The European Tribune is a forum for thoughtful dialogue of European and international issues. You are invited to post comments and your own articles.
Please REGISTER to post.
This is the second batch of vaccines rejected by South Africa, which turned away approximately one million AstraZeneca vaccines earlier in 2020. One study determined that those vaccines, sold to South Africa by the Serum Institute of India, provided little buffer against mild to moderate infections by the COVID-19 variant that is common in the country.
Above all were sub-Saharan lessons learned from HIV/AIDS living lab CONTAINMENT and ebola marketing, to date, not withstanding a decade-long BRICS offensive.
Now? Biden admin announces travel ban for South Africa and 7 other countries, citing new variant
Today the Biden Administration announced a Travel Ban on South Africa and 7 other African nations over the "New COVID Variant"Here was Joe Biden and Kamala Harris when Trump banned Travel: pic.twitter.com/NGVef2nkfS— Benny (@bennyjohnson) November 26, 2021
Today the Biden Administration announced a Travel Ban on South Africa and 7 other African nations over the "New COVID Variant"Here was Joe Biden and Kamala Harris when Trump banned Travel: pic.twitter.com/NGVef2nkfS
AstraZeneca was less effective against the Delta variant and India embargoes sending domestic manufactured vaccines overseas.
Outrageous Defense Production Act still blocking necessary raw materials for Indian Serum Institute COVID-19 vaccine production
"Vooma Vouchers": Over 60's to Get Paid for Vaccinating in SA
The vouchers are set to start going out from 4 November, though anyone in the right age group who gets vaccinated from 1 November should receive one. The vouchers are valid for 30 days, and persons will only receive a voucher for their first vaccine dose. Those coming for their second Pfizer dose, for example, are not eligible.
Covid-19 Vaccine detoxing: conversations on social media around ways to remove or "flush out" the vaccine from the body 'Sapere aude'
HVTN 702 is part of a larger HIV vaccine research endeavor led by the Pox-Protein Public-Private Partnership, or P5 -- a diverse group of public and private organizations working to build on the RV144 trial. P5 members include NIAID, the Bill & Melinda Gates Foundation, and the South African Medical Research Council, which funded HVTN 702; the HIV Vaccine Trials Network (HVTN), headquartered at the Fred Hutchinson Cancer Research Center in Seattle, which conducted HVTN 702; Sanofi Pasteur and GSK, which provided study materials; and the U.S. Military HIV Research Program.
According to Balloux, the variant could have evolved during a "chronic infection of an immunocompromised person, possibly in an untreated HIV/AIDS patient"
by Frank Schnittger - Feb 6 5 comments
by Frank Schnittger - Jan 28 15 comments
by Frank Schnittger - Jan 24 11 comments
by Frank Schnittger - Jan 31 2 comments
by gmoke - Jan 29
by Oui - Jan 21 7 comments
by Frank Schnittger - Jan 18
by gmoke - Jan 18
by Oui - Feb 7
by Frank Schnittger - Feb 65 comments
by Oui - Feb 56 comments
by Oui - Feb 4
by Oui - Feb 33 comments
by Oui - Feb 35 comments
by Oui - Feb 112 comments
by Oui - Feb 1
by Frank Schnittger - Jan 312 comments
by Oui - Jan 29
by Frank Schnittger - Jan 2815 comments
by Oui - Jan 281 comment
by Oui - Jan 27
by Oui - Jan 267 comments
by Oui - Jan 25